Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream could ease painful skin condition

NCT ID NCT07049575

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 16, 2026 · Updated 9 times

Summary

This early-stage trial tests a cream called ruxolitinib on people with hidradenitis suppurativa, a condition causing painful lumps under the skin. The study includes 24 adults and teens and focuses on safety and how much of the drug gets into the body. Participants apply the cream twice daily to affected areas.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ruxolitinib cream
What this could lead to
If it works, this could point toward a topical treatment for hidradenitis suppurativa, reducing painful lumps without systemic drugs.
What could go wrong
This is a very early Phase 1 trial with only 24 people, focused on safety and drug levels, not yet on effectiveness. It may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of HS for at least 6 months before screening visit. * Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits. * Total estimated treatment BSA \> 20% at screening and baseline. * Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period. * Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol. * Further inclusion criteria apply. Exclusion Criteria: * Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator. * Laboratory values outside of the protocol-defined ranges. * Further exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    17 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Amicis Research Center Valencia

    RECRUITING

    Northridge, California, 91324, United States

  • Centricity Research Columbus

    COMPLETED

    Columbus, Ohio, 43213, United States

  • Children'S Hospital of Orange County

    RECRUITING

    Orange, California, 92868, United States

  • Clarity Dermatology

    COMPLETED

    Castle Rock, Colorado, 80109, United States

  • Clinical Trials Research Institute

    RECRUITING

    Thousand Oaks, California, 91320, United States

  • Delricht Research

    RECRUITING

    Baton Rouge, Louisiana, 70809, United States

  • Dr Bobby Buka, Md Greenwich Village

    RECRUITING

    New York, New York, 10012-1354, United States

  • Equity Medical, Llc

    RECRUITING

    Bowling Green, Kentucky, 42104, United States

  • Equity Medical, Llc

    RECRUITING

    New York, New York, 10019, United States

  • First Oc Dermatology

    COMPLETED

    Fountain Valley, California, 92708, United States

  • International Clinical Research Tennessee Llc

    RECRUITING

    Sanford, Florida, 32771, United States

  • Lane Dermatology and Dermatologic Surgery

    RECRUITING

    Columbus, Georgia, 31904, United States

  • Lenus Research Medical Group, Llc

    RECRUITING

    Sweetwater, Florida, 33172, United States

  • Options Research Group, Llc

    RECRUITING

    West Lafayette, Indiana, 47906, United States

  • Paddington Testing Co Inc

    RECRUITING

    Philadelphia, Pennsylvania, 19103, United States

  • Red River Research Partners

    RECRUITING

    Bolivar, Missouri, 65613, United States

  • Red River Research Partners

    RECRUITING

    Fargo, North Dakota, 58103, United States

  • Revival Research Institute, Llc Troy

    COMPLETED

    Troy, Michigan, 48084, United States

  • Saguaro Dermatology

    RECRUITING

    Phoenix, Arizona, 85008, United States

  • Trueblue Clinical Research

    RECRUITING

    Tampa, Florida, 33609, United States

  • Unity Clinical Research

    RECRUITING

    Oklahoma City, Oklahoma, 73118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.